UCHL3 and neoplasm: However, given the complexity of DDR regulation and tumor immune microenvironments, further studies are necessary to evaluate the therapeutic window, off-target effects, and optimal patient selection criteria before UCHL3-targeted strategies can be translated into clinical application.